Submitted by Anonymous (not verified) on 20 November 2023 - 13:55
Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 14, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Breast Neoplasms, Date of authorisation: 22/08/2017, Revision: 14, Status: Authorised